Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More
Protein Biochips - On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. On the surface… Read More
By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed at restricting the utilisation… Read More
Proteomatics - New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Somewhat more prosaically, industrial bioinformatics… Read More
The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well into the 21st. Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and to use… Read More
By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More
Drug development for skin diseases based on functional genomics By Dr Jorn-Peter Halle With the high number of sufferers from skin disease around the world, it is astonishing that there are relatively few treatments available and that many of these only serve to relieve symptoms. Can drug development based on… Read More
Fine-tuning the technology strategies for lead finding By Sandra Fox, Dr Shauna Farr-Jones, Dr Lynne Sopchak and Dr Helen Wang HTS has become the workhorse of pharmaceutical and biotechnology companies' drug discovery efforts, with expanding responsibilities and increasing pressures to screen more targets with better compound libraries to find high-quality… Read More
SNP Genotyping in Drug Development By Dr Nicholas C. Dracopoli and Dr Kim E. Zerba SNP-based candidate gene analyses are likely to have a significant impact on predicting drug efficacy and will, undoubtedly, impact on the pharmaceutical industry's development strategies as a whole over the next few years. The human… Read More
High throughput genomics and drug discovery - parallel universes or a continuum? By Dr Mark Beggs and Audrey Long HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a 'high throughput' mode for approximately four years for… Read More
By Dr Mark L. Nelson Less than a hundred years ago, if you developed a microbial infection your immune system couldnt handle, you died. Then came the wonder drugs, antibiotics capable of fighting the infections for you. But times have changed. Now, because of antibiotics, their use and misuse, the… Read More
Chemical microarrays - The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool of genomic data and countless unvalidated targets… Read More
Obesity - The 21st century disease By Diane L. McBay and Dr Colin T. Dourish Obesity will be the leading cause of death and disability in the 21st century. This epidemic is largely attributable to increasingly sedentary lifestyles and the abundance of tasty, high-fat foods. Obesity increases the risk of… Read More
Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More
Business strategy for implementation of biomarkers in drug development By Miles Flamenbaum With pharmacoproteomic biomarkers being the subject of focus among regulatory agencies as well as research institutions, many pharmaceutical companies are increasing their interest and investment in biomarker strategies. This article discusses the potential for new efficiencies and cost… Read More